AMERICAN JOURNAL OF PSYCHIATRY
Fecha de publicación: 19 Jul 2018
DOI: https://doi.org/10.1176/appi.ajp.2018.17080858
Autores: Josh M. Krivinko, B.S., Susan L. Erickson, Ph.D., Ying Ding, Ph.D., Zhe Sun, M.S., Peter Penzes, Ph.D., Matthew L. MacDonald, Ph.D., Nathan A. Yates, Ph.D., Milos D. Ikonomovic, M.D., Oscar L. Lopez, M.D., Robert A. Sweet, M.D., Julia Kofler, M.D.
Background: The presence of psychosis in Alzheimer’s disease denotes a phenotype with more rapid cognitive deterioration than in Alzheimer’s disease without psychosis. Discovery of novel pharmacotherapies that engage therapeutic targets for prevention or treatment of Alzheimer’s disease with psychosis would benefit from identifying the neurobiology of resilience to psychosis in Alzheimer’s disease. The primary objective of this study was to determine whether alterations in the synaptic proteome were associated with resilience to psychotic symptoms in Alzheimer’s disease and, if present, were independent of neuropathologic burden.
